524 related articles for article (PubMed ID: 32140709)
21. β-escin reverses multidrug resistance through inhibition of the GSK3β/β-catenin pathway in cholangiocarcinoma.
Huang GL; Shen DY; Cai CF; Zhang QY; Ren HY; Chen QX
World J Gastroenterol; 2015 Jan; 21(4):1148-57. PubMed ID: 25632187
[TBL] [Abstract][Full Text] [Related]
22. Retinoid X receptor α enhances human cholangiocarcinoma growth through simultaneous activation of Wnt/β-catenin and nuclear factor-κB pathways.
Huang GL; Zhang W; Ren HY; Shen XY; Chen QX; Shen DY
Cancer Sci; 2015 Nov; 106(11):1515-23. PubMed ID: 26310932
[TBL] [Abstract][Full Text] [Related]
23. Bufalin targeting CAMKK2 inhibits the occurrence and development of intrahepatic cholangiocarcinoma through Wnt/β-catenin signal pathway.
Zhang H; Dong X; Ding X; Liu G; Yang F; Song Q; Sun H; Chen G; Li S; Li Y; Wang M; Guo T; Zhang Z; Li B; Yang L
J Transl Med; 2023 Dec; 21(1):900. PubMed ID: 38082327
[TBL] [Abstract][Full Text] [Related]
24. Long non-coding RNA LINC00665 promotes gemcitabine resistance of Cholangiocarcinoma cells via regulating EMT and stemness properties through miR-424-5p/BCL9L axis.
Lu M; Qin X; Zhou Y; Li G; Liu Z; Geng X; Yue H
Cell Death Dis; 2021 Jan; 12(1):72. PubMed ID: 33436545
[TBL] [Abstract][Full Text] [Related]
25. MicroRNA-26a promotes cholangiocarcinoma growth by activating β-catenin.
Zhang J; Han C; Wu T
Gastroenterology; 2012 Jul; 143(1):246-56.e8. PubMed ID: 22484120
[TBL] [Abstract][Full Text] [Related]
26. PRKAR1A is overexpressed and represents a possible therapeutic target in human cholangiocarcinoma.
Loilome W; Juntana S; Namwat N; Bhudhisawasdi V; Puapairoj A; Sripa B; Miwa M; Saya H; Riggins GJ; Yongvanit P
Int J Cancer; 2011 Jul; 129(1):34-44. PubMed ID: 20824711
[TBL] [Abstract][Full Text] [Related]
27. Tetraspanin 1 promotes epithelial-to-mesenchymal transition and metastasis of cholangiocarcinoma via PI3K/AKT signaling.
Wang Y; Liang Y; Yang G; Lan Y; Han J; Wang J; Yin D; Song R; Zheng T; Zhang S; Pan S; Liu X; Zhu M; Liu Y; Cui Y; Meng F; Zhang B; Liang S; Guo H; Liu Y; Hassan MK; Liu L
J Exp Clin Cancer Res; 2018 Dec; 37(1):300. PubMed ID: 30514341
[TBL] [Abstract][Full Text] [Related]
28. Gambogic Acid Inhibits Wnt/β-catenin Signaling and Induces ER Stress-Mediated Apoptosis in Human Cholangiocarcinoma.
Suksen K; Janpipatkul K; Reabroi S; Anantachoke N; Reutrakul V; Chairoungdua A; Thongon N; Bhukhai K
Asian Pac J Cancer Prev; 2021 Jun; 22(6):1913-1920. PubMed ID: 34181351
[TBL] [Abstract][Full Text] [Related]
29. Knockdown of tripartite motif 59 (TRIM59) inhibits proliferation in cholangiocarcinoma via the PI3K/AKT/mTOR signalling pathway.
Shen H; Zhang J; Zhang Y; Feng Q; Wang H; Li G; Jiang W; Li X
Gene; 2019 May; 698():50-60. PubMed ID: 30822475
[TBL] [Abstract][Full Text] [Related]
30. γ-aminobutyric acid B2 receptor: A potential therapeutic target for cholangiocarcinoma in patients with diabetes mellitus.
Saengboonmee C; Sorin S; Sangkhamanon S; Chomphoo S; Indramanee S; Seubwai W; Thithuan K; Chiu CF; Okada S; Gingras MC; Wongkham S
World J Gastroenterol; 2023 Jul; 29(28):4416-4432. PubMed ID: 37576707
[TBL] [Abstract][Full Text] [Related]
31. Forced overexpression of FBP1 inhibits proliferation and metastasis in cholangiocarcinoma cells via Wnt/β-catenin pathway.
Zhao W; Yang S; Chen J; Zhao J; Dong J
Life Sci; 2018 Oct; 210():224-234. PubMed ID: 30193944
[TBL] [Abstract][Full Text] [Related]
32. PRKAR1A overexpression is associated with increased ECPKA autoantibody in liver fluke-associated cholangiocarcinoma: application for assessment of the risk group.
Loilome W; Yooyuen S; Namwat N; Sithithaworn P; Puapairoj A; Kano J; Noguchi M; Miwa M; Yongvanit P
Tumour Biol; 2012 Dec; 33(6):2289-98. PubMed ID: 22922884
[TBL] [Abstract][Full Text] [Related]
33. Survey of activated kinase proteins reveals potential targets for cholangiocarcinoma treatment.
Dokduang H; Juntana S; Techasen A; Namwat N; Yongvanit P; Khuntikeo N; Riggins GJ; Loilome W
Tumour Biol; 2013 Dec; 34(6):3519-28. PubMed ID: 23812726
[TBL] [Abstract][Full Text] [Related]
34. Wnt signalling modulates transcribed-ultraconserved regions in hepatobiliary cancers.
Carotenuto P; Fassan M; Pandolfo R; Lampis A; Vicentini C; Cascione L; Paulus-Hock V; Boulter L; Guest R; Quagliata L; Hahne JC; Ridgway R; Jamieson T; Athineos D; Veronese A; Visone R; Murgia C; Ferrari G; Guzzardo V; Evans TRJ; MacLeod M; Feng GJ; Dale T; Negrini M; Forbes SJ; Terracciano L; Scarpa A; Patel T; Valeri N; Workman P; Sansom O; Braconi C
Gut; 2017 Jul; 66(7):1268-1277. PubMed ID: 27618837
[TBL] [Abstract][Full Text] [Related]
35. YBX1 promotes stemness and cisplatin insensitivity in intrahepatic cholangiocarcinoma via the AKT/β-catenin axis.
Shi X; Hu Z; Bai S; Zong C; Xue H; Li Y; Li F; Chen L; Xuan J; Xia Y; Wei L; Shen F; Wang K
J Gene Med; 2024 May; 26(5):e3689. PubMed ID: 38676365
[TBL] [Abstract][Full Text] [Related]
36. Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma.
Ewald F; Grabinski N; Grottke A; Windhorst S; Nörz D; Carstensen L; Staufer K; Hofmann BT; Diehl F; David K; Schumacher U; Nashan B; Jücker M
Int J Cancer; 2013 Nov; 133(9):2065-76. PubMed ID: 23588885
[TBL] [Abstract][Full Text] [Related]
37. Involvement of Wnt/β-catenin signaling in the mesenchymal stem cells promote metastatic growth and chemoresistance of cholangiocarcinoma.
Wang W; Zhong W; Yuan J; Yan C; Hu S; Tong Y; Mao Y; Hu T; Zhang B; Song G
Oncotarget; 2015 Dec; 6(39):42276-89. PubMed ID: 26474277
[TBL] [Abstract][Full Text] [Related]
38. Mitochondrial transplantation inhibits cholangiocarcinoma cells growth by balancing oxidative stress tolerance through PTEN/PI3K/AKT signaling pathway.
Liu X; Zhang Y; Yang X; Zhang Y; Liu Y; Wang L; Yi T; Yuan J; Wen W; Jian Y
Tissue Cell; 2023 Dec; 85():102243. PubMed ID: 37865041
[TBL] [Abstract][Full Text] [Related]
39. WNT signaling drives cholangiocarcinoma growth and can be pharmacologically inhibited.
Boulter L; Guest RV; Kendall TJ; Wilson DH; Wojtacha D; Robson AJ; Ridgway RA; Samuel K; Van Rooijen N; Barry ST; Wigmore SJ; Sansom OJ; Forbes SJ
J Clin Invest; 2015 Mar; 125(3):1269-85. PubMed ID: 25689248
[TBL] [Abstract][Full Text] [Related]
40. Activation of the PI3K-AKT signaling pathway by SPARC contributes to the malignant phenotype of cholangiocarcinoma cells.
Deng S; Zhang L; Li J; Jin Y; Wang J
Tissue Cell; 2022 Jun; 76():101756. PubMed ID: 35217388
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
